Alnylam HELIOS-B Vutrisiran Phase 3 Results 2024

Alnylam Pharmaceuticals presents positive topline results from the HELIOS-B Phase 3 clinical trial of vutrisiran for ATTR amyloidosis with cardiomyopathy. The presentation covers clinical data, commercialization strategy, and positioning of vutrisiran as a potential first-line RNAi therapeutic for both polyneuropathy and cardiomyopathy manifestations of ATTR.